GRGDSPK

GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption^[1][2]. In Vitro: GRGDSPK (EMD 56574; RGD; 0.1-50 μM; for 4 days) inhibits mineralization in a dose-dependent manner as determined by measuring calcium content and 70 bonehnit area of tissue in parietal bones 18 days old isolated from pregnant Sprague-Dawley rats^[1].
GRGDSPK (10, 50 μM; for 4 days) dramatically alteres bone morphology, with a disruption of osteoblast and mineralized matrix organization^[1].
GRGDSPK (RGD; 250 μM), added to the medium, effectively blocks integrin-fibronectin binding and significantly increases the average size of wild-type cell aggregates^[2].
When GRGDSPK (250 μM) is added, wild-type mesendodermal progenitors exhibits strongly reduced adhesion forces and work, indicating that the detachment parameters recorded are specific for fibronectin and that integrins expressed in mesendodermal progenitors are involved^[2].
GRGDSPK (RGD-containing, 1.5 mM, 1.0 mM, and 0.5 mM) and RGD-mod-ified peptides impair the ability of sperm to fertilizebovine oocytes, illustrated by a reduction in cleavage in a dose-dependent manner^[3].